{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T18:32:31Z","timestamp":1777573951529,"version":"3.51.4"},"reference-count":46,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2018,3,6]],"date-time":"2018-03-06T00:00:00Z","timestamp":1520294400000},"content-version":"vor","delay-in-days":33,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Epileptic Disorders"],"published-print":{"date-parts":[[2018,2]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>Rufinamide was granted orphan drug status in 2004 for the adjunctive treatment of seizures associated with Lennox\u2010Gastaut syndrome in patients aged \u22654 years, and was subsequently approved for this indication in several countries, including Europe and the United States. Structurally unrelated to other antiepileptic drugs, rufinamide is thought to act primarily by prolonging the inactivation phase of voltage\u2010gated sodium channels. Rufinamide was approved on the basis of an international, randomised, placebo\u2010controlled Phase III trial, conducted in 138 patients with Lennox\u2010Gastaut syndrome, which demonstrated its favourable tolerability profile and efficacy in significantly reducing the frequency of drop attacks and total seizures, compared with placebo. The effectiveness and safety\/tolerability of rufinamide in treating seizures associated with Lennox\u2010Gastaut syndrome have subsequently been confirmed in several other clinical trials and long\u2010term extension studies. These findings are supported by \u2018real\u2010world\u2019 data from a series of clinical practice studies conducted in Europe, the United States, and Korea. Rufinamide has been shown to be effective and generally well tolerated in children as young as one year and in adults. It is particularly effective as treatment for drop attacks and generalised tonic\u2010clonic seizures, and it has been suggested that it might be preferred over other antiepileptic drugs as a second\u2010line treatment for Lennox\u2010Gastaut syndrome when drop attacks are frequent. The most common side effects of rufinamide treatment include somnolence, headache, dizziness, nausea, vomiting, and fatigue. No new or unexpected safety signals have emerged following long\u2010term treatment with rufinamide, either in clinical trials or in clinical practice.<\/jats:p>","DOI":"10.1684\/epd.2017.0950","type":"journal-article","created":{"date-parts":[[2019,8,2]],"date-time":"2019-08-02T13:24:29Z","timestamp":1564752269000},"page":"13-29","source":"Crossref","is-referenced-by-count":26,"title":["Rufinamide for the treatment of Lennox\u2010Gastaut syndrome: evidence from clinical trials and clinical practice"],"prefix":"10.1002","volume":"20","author":[{"given":"Pasquale","family":"Striano","sequence":"first","affiliation":[{"name":"Paediatric Neurology and Muscular Diseases Unit, Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health University of Genoa, G. Gaslini Institute Genova Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rob","family":"McMurray","sequence":"additional","affiliation":[{"name":"Eisai Europe Ltd Hatfield UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Estevo","family":"Santamarina","sequence":"additional","affiliation":[{"name":"Hospital Vall d'Hebron Barcelona"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Merc\u00e8","family":"Falip","sequence":"additional","affiliation":[{"name":"Hospital de Bellvitge Barcelona Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2018,3,6]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(08)70292-8"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpn.2015.12.015"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1684\/epd.2011.0422"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1684\/epd.2011.0408"},{"key":"e_1_2_10_6_1","first-page":"111","article-title":"Use of adjunctive rufinamide for patients with Lennox\u2010Gastaut syndrome in clinical practice","volume":"55","author":"Auvin S.","year":"2014","journal-title":"Epilepsia"},{"key":"e_1_2_10_7_1","unstructured":"AuvinS PaponA BellavoineV et al.Use of adjunctive rufinamide for patients with Lennox\u2010Gastaut syndrome in clinical practice. Poster presented at 11thEuropean Congress on Epileptology Stockholm Sweden; June 29\u2010July 03 2014b."},{"key":"e_1_2_10_8_1","unstructured":"Banzel\u00aePrescribing Information.Eisai Inc. 2015. Available at:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/021911s013 201367s005lbl.pdf. Accessed 25 July 2017."},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2009.02160.x"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2010.09.008"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpn.2014.05.008"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2017.00505"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpn.2008.12.005"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1021\/cb500108p"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000303813.95800.0d"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpn.2014.05.001"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.8.12.1931"},{"key":"e_1_2_10_18_1","first-page":"CD003277","article-title":"Treatment of Lennox\u2010Gastaut syndrome","volume":"2","author":"Hancock E.C.","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_10_19_1","unstructured":"Inovelon\u00aeSummary of Product Characteristics.Eisai Ltd.Available at:http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000660\/WC500032937.pdf. Accessed 25 July2017."},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.9.4.829"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/ane.12572"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1684\/epd.2011.0409"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2015.02.003"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2012.02.006"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.14581\/jer.12009"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1684\/epd.2013.0557"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2014.11.004"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2008.12.013"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0404.2010.01334.x"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2010.01.005"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2012.09.021"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0b013e31820fa9ad"},{"key":"e_1_2_10_33_1","first-page":"296","article-title":"The influence of rufinamide on sodium currents and action potential firing in rodent neurons","volume":"46","author":"McLean M.J.","year":"2005","journal-title":"Epilepsia"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-016-0041-9"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.12732"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2012.03579.x"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2011.04.057"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2014.08.019"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2016.01.002"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2008.01665.x"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1684\/epd.2011.0421"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hrthm.2012.01.006"},{"key":"e_1_2_10_43_1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.12689"},{"key":"e_1_2_10_44_1","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S1668"},{"key":"e_1_2_10_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pediatrneurol.2010.04.003"},{"key":"e_1_2_10_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpn.2011.12.012"},{"key":"e_1_2_10_47_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2008.01552.x"}],"container-title":["Epileptic Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1684\/epd.2017.0950","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,18]],"date-time":"2024-03-18T16:04:31Z","timestamp":1710777871000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1684\/epd.2017.0950"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["10.1684\/epd.2017.0950"],"URL":"https:\/\/doi.org\/10.1684\/epd.2017.0950","archive":["Portico"],"relation":{},"ISSN":["1294-9361","1950-6945"],"issn-type":[{"value":"1294-9361","type":"print"},{"value":"1950-6945","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2]]}}}